Back to results
US 12,595,304 B2Granted
Antibodies specific to glycosylated LAG3 and methods of use thereof
AssigneeStcube, Inc.
InventorStephen S. Yoo
Life of this patent
Estimating the term…
Abstract
Antibodies that selectively bind to glycosylated LAG3 relative to unglycosylated LAG3 are provided. In some aspects, LAG3 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
Claims19
An isolated monoclonal antibody which selectively binds to glycosylated LAG3 relative to unglycosylated form of LAG3,
- said isolated monoclonal antibody having (I) a VH domain comprising (a) a Chothia CDR H1 with the amino acid sequence of SEQ ID NO:
- 6, a CDR H2 with the amino acid sequence of SEQ ID NO:
- 7, and a CDR H3 with the amino acid sequence of SEQ ID NO:
- 8 (b) an AbM CDR H1 with the amino acid sequence of SEQ ID NO:
- 9, a CDR H2 with the amino acid sequence of SEQ ID NO:
- 10, and a CDR H3 with the amino acid sequence of SEQ ID NO:
- 8;
- or (c) a Kabat CDR H1 with the amino acid sequence of SEQ ID NO:
- 11, a CDR H2 with the amino acid sequence of SEQ ID NO:
- 12, and a CDR H3 with the amino acid sequence of SEQ ID NO:
- 8;
- and (II) a VL domain comprising a CDR L1 with the amino acid sequence of SEQ ID NO:
- 16, a CDR L2 with the amino acid sequence of SEQ ID NO:
- 17, and a CDR L3 with the amino acid sequence of SEQ ID NO:
- 18, or
- said isolated monoclonal antibody having (I) a VH domain comprising a Contact CDR H1 with the amino acid sequence of SEQ ID NO:
- 13, a CDR H2 with the amino acid sequence of SEQ ID NO:
- 14, and a CDR H3 with the amino acid sequence of SEQ ID NO:
- 15 and (II) a VL domain comprising a Contact CDR L1 with the amino acid sequence of SEQ ID NO:
- 19, a CDR L2 with the amino acid sequence of SEQ ID NO:
- 20, and a CDR L3 with the amino acid sequence of SEQ ID NO:
- 21.
19 more elements
Dependencies are inferred from the claim text.